Cited by 34Hematopoietic Stem Cell TransplantationT-cell and B-cell ImmunologyMesenchymal stem cell research

Adoptive Transfer of Treg Cells Combined with Mesenchymal Stem Cells Facilitates Repopulation of Endogenous Treg Cells in a Murine Acute GVHD Model

Open access
Lee, Eun-Sol, Lim, Jung-Yeon, Im, Keon-Il, Kim, Nayoun, Nam, Young-Sun, Jeon, Young-Woo, Cho, Seok-Goo·2015·PLOS ONE

Abstract

Therapeutic effects of combined cell therapy with mesenchymal stem cells (MSCs) and regulatory T cells (Treg cells) have recently been studied in acute graft-versus-host-disease (aGVHD) models. However, the underlying, seemingly synergistic mechanism behind combined cell therapy has not been determined. We investigated the origin of Foxp3+ Treg cells and interleukin 17 (IL-17+) cells in recipients following allogeneic bone marrow transplantation (allo-BMT) to identify the immunological effects of combined cell therapy. Treg cells were generated from eGFP-expressing C57BL/6 mice (Tregegfp cells) to distinguish the transferred Treg cells; recipients were then examined at different time points after BMT. Systemic infusion of MSCs and Treg cells improved survival and GVHD scores, effectively downregulating pro-inflammatory Th×and Th17 cells. These therapeutic effects of combined cell therapy resulted in an increased Foxp3+ Treg cell population. Compared to single cell therapy, adoptively transferred Tregegfp cells only showed prolonged survival in the combined cell therapy group on day 21 after allogeneic BMT. In addition, Foxp3+ Treg cells, generated endogenously from recipients, significantly increased. Significantly higher levels of Tregegfp cells were also detected in aGVHD target organs in the combined cell therapy group compared to the Treg cells group. Thus, our data indicate that MSCs may induce the long-term survival of transferred Treg cells, particularly in aGVHD target organs, and may increase the repopulation of endogenous Treg cells in recipients after BMT. Together, these results support the potential of combined cell therapy using MSCs and Treg cells for preventing aGVHD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0138846

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 48 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Lee, E.-S., Lim, J.-Y., Im, K.-I., Kim, N., Nam, Y.-S., Jeon, Y.-W., & Cho, S.-G.
Affiliations
  • Catholic University of Korea (KR)
  • The Catholic University of Korea Seoul St. Mary's Hospital (KR)
Corresponding author
Cho, Seok-Goo
Venue
PLOS ONE
Published
2015-09-22
Volume
10
Issue
9
Pages
e0138846
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2293085954
Cited by
34
References
48
Citations by year
2025: 1 · 2023: 7 · 2021: 6 · 2020: 5 · 2019: 3 · 2018: 6 · 2017: 3 · 2016: 2 · 2015: 1
FWCI
3.14
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
Keywords
acute graft-versus-host disease, regulatory T cells, mesenchymal stem cells, adoptive cell transfer, combined cell therapy, allogeneic bone marrow transplantation, Th17 cells, Th1 cells, IL-17, graft-versus-host disease prophylaxis
MeSH terms
Acute Disease, Animals, Cells, Cultured, Combined Modality Therapy, Disease Models, Animal, Graft Survival, Graft vs Host Disease, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Transplantation, Homologous, Gene Expression, Bone Marrow Transplantation, Treatment Outcome, Microscopy, Confocal, Adoptive Transfer, Reverse Transcriptase Polymerase Chain Reaction, Mesenchymal Stem Cell Transplantation, Green Fluorescent Proteins, T-Lymphocytes, Regulatory, Forkhead Transcription Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review